Brief: Ocumension Therapeutics H1 Revenue RMB167.6 Million
12/08/2024 10:43
Aug 12 (Reuters) - Ocumension Therapeutics H1 gross profit RMB 99.2 million. * H1 revenue RMB 167.6 million
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application